Comparative Pharmacology
Head-to-head clinical analysis: PLEGISOL IN PLASTIC CONTAINER versus PLENVU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLEGISOL IN PLASTIC CONTAINER versus PLENVU.
PLEGISOL IN PLASTIC CONTAINER vs PLENVU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PLEGISOL is an extracellular-type crystalloid cardioplegic solution used for myocardial protection during cardiac surgery. Its mechanism involves inducing rapid cardiac arrest by high potassium concentration (depolarizing arrest), reducing myocardial oxygen demand, and providing buffering capacity via tromethamine to maintain pH. The solution also contains magnesium to stabilize membranes and mannitol as an osmotic agent to reduce edema.
PLENVU is an osmotic laxative that induces bowel cleansing by causing water retention in the colon, leading to increased intraluminal pressure and stimulation of peristalsis. Its components (polyethylene glycol 3350, sodium ascorbate, ascorbic acid, sodium sulfate) act synergistically to produce a cathartic effect.
Administered as an intraperitoneal infusion for organ preservation. Typical adult dose: 2.5-3.0 liters for kidney, 2.5-3.0 liters for liver, 3.0-4.0 liters for pancreas, single dose prior to procurement.
2 sachets (each containing ascorbic acid 4.7g, macrogol 3350 52.5g, sodium ascorbate 5.9g, sodium sulfate 3.75g) dissolved in water to a total volume of 500mL, administered orally as a split-dose regimen: first dose (2 sachets in 500mL water) at 6-9 pm on the day before colonoscopy, followed by additional 500mL of clear fluids; second dose (2 sachets in 500mL water) on the morning of colonoscopy, completed at least 2 hours before the procedure, followed by additional 500mL of clear fluids.
None Documented
None Documented
Not applicable; Plegisol is not a systemically active drug. Its cardioplegic effect is immediate upon perfusion into coronary arteries and dissipates upon reperfusion. The solution's components have endogenous half-lives (e.g., potassium: 1-1.5 h in plasma), but this is not clinically relevant for the product.
Not applicable (non-absorbed agent); systemic absorption is minimal, so no terminal half-life is defined.
Plegisol is an extracellular cardioplegic solution; its components (electrolytes and calcium) are not metabolized. Elimination of infused volume occurs primarily via renal excretion (approx. 95%) as unchanged water and electrolytes; minor biliary/fecal elimination (<5%) accounts for negligible electrolyte loss.
Primarily fecal (90-95%) as unabsorbed drug; renal excretion is negligible (<1%).
Category C
Category C
Osmotic Laxative
Osmotic Laxative